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Nadeem R. Abu-Rustum, MD,Ý Hedvig Hricak, MD, PhD,* and Hebert Alberto Vargas, MD*
Objective: The aim of this study was to evaluate the incremental prognostic value of pelvic
magnetic resonance imaging (MRI) and whole-body 18F-fluorodeoxyglucose positron
emission tomography/computed tomography (PET/CT) findings compared with clinical-
histopathologic factors in patients with newly diagnosed cervical cancer.
Methods: The institutional review board approved this retrospective study of 114 patients
(median age, 40.6 years) with International Federation of Gynecology and Obstetrics
(FIGO) stage I-IVB cervical cancer who underwent pretreatment MRI and PET/CT. All
scanswere reviewed for locoregional tumor extent, pelvic or/andpara-aortic lymphadenopathy,
and distant metastases. Univariate Cox proportional hazard regression was performed to
evaluate associations between clinical-histopathologic factors, imaging findings, and
progression-free survival (PFS). Multivariate models were built using independent pre-
dictors for PFS. Harrell C was used to measure concordance (C index).
Results: Forty patients progressed within a median time of 10.4 months (range, 0.4Y40.3
months). At univariate analysis, age, FIGO stage, tumor histology, tumor grade, and all MRI
and PET/CT features were significantly associated with PFS (P G 0.0001 to P = 0.0474). A
multivariate model including clinical and imaging parameters (parametrial invasion on MRI
and para-aortic lymphadenopathy/distant metastases on PET/CT) had significantly higher
concordance for predicting PFS than a model including clinical parameters only (C index:
0.81 [95% confidence interval, 0.75Y0.87] vs 0.68 [95% confidence interval, 0.59Y0.78];
P G 0.001). The comparison of C indices for the combined clinical and imaging model
approached significance when compared with a FIGO stage model (C index: 0.81 [95%
confidence interval, 0.75Y0.87] vs 0.75 [95% confidence interval, 0.69Y0.82]; P = 0.058).
Conclusions: In patients with newly diagnosed cervical cancer, a prognostic model in-
cluding combined MRI and PET/CT findings provides information that complements
clinical and histopathologic factors.
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In patients with newly diagnosed cervical cancer, the pre-diction of prognosis is currently based on the International
Federation of Gynecology and Obstetrics (FIGO) clinical
staging system, which has its known limitations.1,2 The sur-
vival rate of patients with the same FIGO stage may vary3;
therefore, FIGO stage alone may not be entirely satisfac-
tory to accurately provide prognostic information in pa-
tients with cervical cancer. The prognostic relevance of other
pretreatment clinical-histopathologic variables such as pa-
tient’s age, tumor histology and grade, tumor diameter, deep
stromal and parametrial invasion, lymph vascular invasion,
and lymph node (LN) metastases has also been evaluated. In a
study of 187 patients with stage IB2-IIB cervical cancer,
pathologically assessed parametrial invasion and LN status
were predictors of disease-free survival and overall survival
(OS)4 independent of other clinical-histopathologic factors.
Few previous reports have simultaneously analyzed the
prognostic value of multiple variables (including imaging
findings) in patients with cervical cancer to create a nomo-
gram able to provide individualized prediction of outcome.5Y9
These nomograms, which include age, histological subtype,
tumor size, parametrial involvement, pelvic organ invasion,
and LN status, have been shown to compare favorably with
FIGO staging system. In patients with locally advanced cer-
vical cancer (LACC), Kang et al5 developed a 4-parameter
risk assessment model to predict recurrence, which included
pelvic/para-aortic LNmetastasis detected on 18F-fluorodeoxyglucose
(FDG) positron emission tomography/computed tomography
(PET/CT) and clinical-histopathologic factors. In contrast,
Shim et al9 introduced a 3-variable risk assessment model to
predict 5-year survival in patients with LACC, which incor-
porated histology, tumor size, and para-aortic LN metastasis
detected on magnetic resonance imaging (MRI). Both no-
mograms showed high accurate prediction, and their use as an
alternative to FIGO stage system has been suggested. How-
ever, the prognostic value of combining information derived
from MRI, FDG PET/CT, and clinical-histopathologic pa-
rameters in patients with all-stage cervical cancer has not
been reported. This information is particularly important with
the recent introduction of integrated PET/MRI scanners in
clinical use. Positron emission tomography/MRI is able to
provide integrated anatomic, metabolic, and functional in-
formation. In the future, specific PET/MRI acquisition and
interpretation protocols that provide information useful to
predict clinical outcomes in patients with cervical cancer need
to be developed. Hence, the aims of our study were to (1)
evaluate the prognostic value of pelvicMRI, whole-body FDG
PET/CT, and clinical-histopathologic factors in the pretreatment
assessment of patients with FIGO stage I to IV cervical cancer
and (2) assess the added value of a combinedMRI and whole-
body FDG PET/CT qualitative imaging parameters and clinical-
histopathologic factors, compared with clinical-histopathologic
factors alone.
MATERIALS AND METHODS
The institutional review board approved and issued
a waiver of informed consent for this retrospective study,
which was compliant with the Health Insurance Portability
and Accountability Act.
Patient Cohort
Review of our prospectively maintained uterine cervi-
cal cancer database identified 116 patients with pathologi-
cally proven cervical cancer who underwent pelvic MRI and
FDG PET/CT for initial staging prior to primary treatment
(surgery and/or chemoradiotherapy) at our institution be-
tween November 2005 and May 2012. Two patients were
excluded from the analysis because no follow-up information
was available; thus, our study cohort included 114 patients.
Forty-nine patients have been included in a previous pub-
lished study evaluating the use of quantitative FDG uptake
(PET) and diffusion (MRI) metrics in the assessment of
cervical cancer.7
Imaging Protocol
Magnetic resonance imaging was performed on a 1.5-T
(SignaorDiscoveryMR450;GEMedical Systems,Milwaukee,
WI) or 3-T (Signa HDxt or Discovery MR750; GE Medical
Systems) system using a body coil for excitation and a multi-
channel phased-array coil for signal reception. Specific MRI
parameters varied during the study period, following changes in
our standard clinical protocol, but all examinations included an
axial T1-weighted fast-spin-echo sequence and T2-weighted
fast-spin-echo sequences in 3 imaging planes (axial/sagittal/
axial oblique perpendicular to the cervix). Contrast-enhanced
MRI scans were obtained with a 3-dimensional spoiled gradient-
pulse T1-weighted LAVA (liver acquisition volume accelera-
tion) sequence before and after administration of 0.1 mmol/kg
of gadolinium at a rate of 2 mL/s, which was followed by a
20-mL saline bolus injection.
All patients were scanned on dedicated PET/CT sys-
tems (Discovery STE, LS, or 690 [GE Medical Systems];
Biograph 16 [Siemens Medical Systems]). A clinical imaging
protocol was applied with injection of 400 to 455 MBq FDG
after 6-hour fasting and blood glucose level of less than
200 mg/dL followed by approximately 60-min uptake period.
Subsequently, a low-dose, attenuation correction CT scan
(120Y140 kV, 80 mA) was acquired, followed by PET emis-
sion images from the midthighs to skull base.
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Images Analysis and Interpretation
Magnetic resonance imaging and FDG PET/CT ex-
aminations were retrospectively reviewed by a radiologist
with 5 years of experience in gynecologic cancer imag-
ing, using our institution’s Picture Archiving and Commu-
nication System (Centricity; GE Medical Systems). The
reader was blinded to clinical and histopathologic informa-
tion. The reader evaluated all MRIs, followed by the PET/
CTs. The reader recorded orthogonal tumor diameters; the
distance between the tumor and internal cervical os; the
presence of cervical stromal invasion; parametrial involve-
ment; vaginal extension (lower one third and upper two thirds);
bladder, rectum, and/or pelvic sidewall invasion; presence of
pelvic and/or para-aortic lymphadenopathy; and distant me-
tastasis. The 3 orthogonal tumor diameters were measured on
axial and sagittal fast-spin-echo T2-weighted images (T2WIs).
On MRI, diagnostic criteria of parametrial invasion were full-
thickness disruption of the normal T2WI hypointense cervi-
cal stroma, spiculated tumor-parametrium interface (referred to
as spiculated tumor), soft-tissue extension into the parametria,
or encasement of the periuterine vessels. Vaginal extension was
diagnosed when an interruption of the normal T2WI hypo-
intense vaginal wall was observed. On MRI, bladder and/or
rectal involvement was diagnosed when an interruption of the
normal T2WI hypointense bladder or rectal wall was observed,
with tumor nodules seen in the mucosal layer on T2WI. On
MRI, diagnostic criterion for pelvic sidewall invasion was tu-
mor extending within 3 mm and abutting the obturator internus
or piriformis muscles, with concomitant loss of the normally
present intervening fat planes.
On PET/CT, bladder or rectum involvement was di-
agnosed when direct contact between the FDG avid tumor and
the organ was observed, with concomitant absence of a fat
plane evidenced on the CT component of the examination.
Similarly, pelvic sidewall invasion was diagnosed in the pres-
ence of direct contact between the FDG avid tumor and obtu-
rator internus and/or piriformis muscle.
On MRI, pelvic and para-aortic LNs were considered
metastatic if their short axis were more than 1 cm, or more
than 0.8 cm if they had irregular borders and/or round shape.
Lymph nodes showing FDG uptake above the background
activity on PET images were considered metastatic. Focal
areas of FDGuptake above the background activity located in
the liver, lung, and thorax were considered distant metastasis.
Each of the imaging features pertaining to the regional tumor
spread, nodal involvement, and distant metastases were assessed
on a qualitative 1- to 5-point scale as follows: 1 = definitely
absent, 2 = probably absent, 3 = indeterminate, 4 = probably
present, and 5 = definitely present. Any imaging feature scored
as 4 or 5 was considered a positive finding.
Outcome Data
One of the authors reviewed the patients’ electronic med-
ical records. All patients were evaluated after treatment every
3 months until death or last contact. Progression of disease
was defined as the presence of tumor at biopsy or disease
progression on follow-up imaging according to RECIST
(Response Evaluation Criteria in Solid Tumors) 1.1.10
Statistical Analysis
Descriptive statistics were calculated, including frequen-
cies and percentages for categorical variables and medians and
ranges for continuous variables. For the purpose of analysis,
FIGO stage was grouped into I-IIA versus IIB-IVB, grade (G)
was grouped as 1/2 versus 3, and histology was dichotomized as
squamous cell carcinoma (SCC) versus non-SCC. Pathological
FIGO stage was used in patients who underwent surgery instead
of pretreatment clinical FIGO stage. Age at diagnosis, maximum
tumor diameter on MRI, and tumor volume were evaluated as
continuousmeasurements.Organ involvement onMRIandPET/
CTwas categorized as positive or negative. Para-aortic LN me-
tastasis and distant metastases detected on PET/CTwere com-
bined to indicate disease outside the pelvis. Imaging parameters
with 10 or more positive cases were included in the analysis.
Univariate Cox proportional hazard regression was used
to assess the relationship between imaging parameters and
progression-free survival (PFS). Given the limited number of
events, only a bivariate model could be built for OS, which
would not allow for sufficient assessment of imaging param-
eters’ incremental value. Therefore, only PFS was assessed at
the univariate and multivariate levels. The 2 modalities, MRI
and PET, were analyzed separately. We used the methods of
Lin et al11 to assess the proportional assumption. Progression-
free survival was defined as the interval between first imaging
date and date of last follow-up, date of death, or date of first
progression. Patients free of pelvic and extrapelvic disease and
alive at last follow-up were censored. P G 0.05 was considered
statistically significant.
Multicolinearity was assessed using Spearman corre-
lations. Any 2 variables with a correlation, Q 9 0.50 were
considered nonindependent and not included in multivariate
analysis. Variables significant at P G 0.05 on univariate
analyses and clinically meaningful prognostic indicators were
considered for multivariate analysis. Multivariate analyses
were performed for PFS using Cox proportional hazards re-
gression. We used the standard event per variable rule de-
veloped by Peduzzi et al12 to determine the maximum number
of parameters allowed in the multivariate model.
Based on prior clinical prognostic indicators, age and
grade comprised our baseline clinical model. Parametrial in-
vasion on MRI and para-aortic lymphadenopathy/distant me-
tastasis were added to create the full model. The multivariate
models’ discriminatory ability was calculated using the con-
cordance index (C index), Harrell C, with jackknife 95%
confidence intervals (CIs). We compared the C indices of the
multivariate model including clinical and imaging parameters
with themodel including clinical parameters only and the FIGO
stage model. As this was a retrospective, exploratory study, no
corrections were made for multiple hypothesis testing. All
analyses were performed using SAS 9.2 (SAS Institute, Cary,
NC) and Stata SE 12 (StataCorp, College Station, TX).
RESULTS
Patients Characteristics
Patient characteristics are summarized in Table 1. The
median age at diagnosis was 40.1 years (range, 18.2Y88.9
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years), and the median time between MRI and PET/CT was
3 days (range, 0Y50 days). Patients were treated per standard
of care at our institution with surgery alone (32.5%),
chemoradiation-therapy (CRT) alone (43.9%), or surgery and
CRT (21.0%). The median follow-up time was 25.8 months
(range, 0.3Y84.8 months). The median time to progression
was 10.4 months (range, 0.4Y40.3 months). At the end of
follow-up, 24 patients had died of disease (21.1%), and an
additional 16 patients progressed but were alive (14.0%).
Progression-Free Survival
Univariate Analyses
FIGO stage (P G 0.0001), age at diagnosis (P = 0.0001),
tumor grade (P = 0.0455), and histology (P = 0.0017) were
significantly associated with PFS. Patients with FIGO stage
IIB-IVB, tumor grade 3, and increased age were at increased
risk for progression. All MRI and PET/CT parameters assessed
were associated with PFS: distance of tumor to the internal
cervical os on MRI (P = 0.0474), maximum diameter on MRI
(P G 0.0001), tumor volume (P G 0.0001) on MRI, parame-
trial invasion on MRI (P G 0.0001), spiculated tumor on
MRI (P G 0.0001), vessel encasement on MRI (P G 0.0001),
vaginal invasion on MRI (P G 0.0001), bladder invasion on
MRI (P G 0.0001), pelvic sidewall invasion on PET and MRI
(P G 0.0001 for both), pelvic lymphadenopathy on PET and
MRI (P G 0.001 for both), and para-aortic lymphadenopathy/
distant metastases on PET (P G 0.0001). Presence of features
or positivity of invasion increased the risk of progression,
(Table 2).
Multivariate Analyses
Our statistical design allowed a maximum of 4 variables
to be used in multivariate analysis (Table 3). Multicolinearity
was present among pelvic sidewall invasion, parametrial
invasion, pelvic lymphadenopathy, spiculated tumor, tumor
volume,maximumdiameter, and vaginal involvement location,
indicating a lack of independence among these parameters.
Therefore, based on clinical significance and prognostic indi-
cation on univariate analyses, parametrial invasion was chosen
to represent theMRIparameters. Para-aortic lymphadenopathy/
distant metastasis assessed on PET/CT was chosen to rep-
resent PET/CT parameters given its relative independence
and clinical importance.
Based on prior clinical prognostic indicators, age and
grade comprised our baseline clinical model. Age (P = 0.0001)
and grade (P = 0.0315) were both significant in themultivariate
model with a C index of 0.68 (95% CI, 0.59Y0.78). When
parametrial invasiononMRI andpara-aortic lymphadenopathy/
distant metastasis were added to create the full model, only
grade (P = 0.0375), parametrial invasion (P = 0.005), and para-
aortic lymphadenopathy/distant metastasis (P = 0.0395) re-
mained significant. The concordance index rose to0.81 (95%CI,
0.75Y0.87), which was significantly different from the baseline
clinical model (P G 0.001). This indicated that imaging pa-
rameters add significant incremental value to clinical prog-
nostic indicators. We then compared the concordance index of
the model of FIGO Stage alone to the full model and this
difference approached significance (P = 0.058).
DISCUSSION
In this study, we demonstrated a significant incremental
prognostic value of pretreatment MRI and FDG PET/CT
findings to clinical and histopathologic prognostic indicators
in patients with newly diagnosed cervical cancer. When im-
aging findings were incorporated into a multivariate model
together with clinical-histopathologic factors, the concor-
dance index was significantly higher than a model with
clinical factors alone, indicating that the full model that in-
cludes pretreatment imaging findings had superior alignment
between the predicted and observed survival times. Similar
to our findings, previous studies showed more accurate
predictive ability of models that included qualitative imaging
parameters and clinical-pathological factors compared with
FIGO stage alone. However, these studies focused only on
high-risk cohorts of patients with LACC treated with defin-
itive CRT,5,13 thus unable to construct a prognostic model,
which is, by definition, independent of treatment received.
Only 1 previous study constructed and validated a prognostic
model of clinical-pathological factors alone (with no added
imaging findings) in a large cohort of cervical cancer patients
including FIGO stage I to IV.8 In another study of 187 patients
with stage IB2-IIB cervical cancer, Gadducci et al4 found that
TABLE 1. Clinical and pathologic patient characteristics
Continuous Variables Median Min-Max
Age at diagnosis, y 40.64 18.22Y88.93
Time between scans, d 3 0.00Y50.00
Time to progression, mo 10.4 0.36Y40.34
(n = 40)
Categorical Variables n %
Histology
Non-SCC 49 42.98
SCC 65 57.02
Grading
Grade 1/2 67 58.77
Grade 3 47 41.23
FIGO stage
I-IIA 60 52.63
IIB-IVB 54 47.37
Death
Alive 90 78.95
Dead 24 21.05
Progression
No 74 64.91
Yes 40 35.09
Treatment
CRT only 50 43.86
Surgery only 37 32.46
Surgery + CRT 27 23.68
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pathologically assessed parametrial invasion and LN status
were predictors of disease-free survival and OS independent
of other clinical-histopathologic factors. In contrast, in our
study, MRI assessment of parametrial invasion and LN
status on PET/CTwere predictors of PFS. This is important as
MRI is widely used to assess parametrial invasion and PET/
CT to assess LN status prior to treatment decision (surgery vs
radiotherapy). For example, patients with findings of pa-
rametrial invasion on MRI do not usually undergo surgery;
they have radiotherapy instead, so histological confirmation
is not possible in all cases. To the best of our knowledge,
our study is the first to investigate the incremental prognos-
tic value of combined MRI and FDG PET/CT qualitative
parameters and clinical-pathological factors compared with
clinical-pathological factors alone in the pretreatment as-
sessment of patients with all-stage cervical cancer.
In patients with newly diagnosed cervical cancer, the
prognostic prediction is currently based on FIGO staging
system. International Federation of Gynecology and Obstet-
rics stage is based on clinical examination, and the system’s
limitations have been described.1,2 Moreover, the risk of re-
currence in patients with early stage of disease has been
reported to range between 5% and 30%.14 Polterauer and
colleagues8 built a nomogram incorporating FIGO stage,
patient’s age, tumor histology, LN status, tumor size, and
parametrial invasion to predict survival in patients with stage
I-IV. We found that the prognostic ability of models including
MRI and FDG PET/CT parameters was higher than FIGO
TABLE 2. Univariate cox proportional hazards regression for PFS
PFS n Progressed Hazard Ratio 95% CI P
Clinical
parameters
Variable Level
Age at diagnosis 114 40 1.04 1.02Y1.06 G0.0001
Histology SCC 65 31 3.28 1.56Y6.90 0.0017
Non-SCC 49 9 REF
Grading Grade 3 47 20 1.89 1.01Y3.52 0.0457
Grade 1/2 67 20 REF
MRI
parameters
FIGO stage IIB-IVB 54 35 12.07 4.70Y30.98 G0.0001
I-IIA 60 5 REF
MRI Tumor to internal cervical o’s distance 113 40 0.94 0.88Y1.00 0.0472
Maximum diameter 114 40 1.04 1.03Y1.05 G0.0001
Tumor volume 114 40 1.01 1.00Y1.01 G0.0001
Spiculated tumor Yes 63 35 8.04 3.14Y20.59 G0.0001
No 51 5 REF
Vessel encasement Yes 26 21 6.13 3.26Y11.52 G0.0001
No 88 19 REF
Parametrial invasion Positive 66 38 19.54 4.71Y81.13 G0.0001
Negative 48 2 REF
Vaginal invasion location Lower one third 5 5 25.92 7.34Y91.59 G0.0001
Upper two thirds 55 30 8.79 3.40Y22.72 G0.0001
None 54 5 REF
Pelvic Sidewall Invasion Positive 38 29 8.22 4.07Y16.57 G0.0001
Negative 76 11 REF
Bladder Invasion Positive 13 12 5.93 2.97Y11.80 G0.0001
Negative 101 28 REF
Pelvic LN involvement Positive 60 32 5.5 2.51Y12.06 G0.0001
Negative 54 8 REF
PET/CT
parameters
Pelvic sidewall invasion Positive 17 14 4.21 2.18Y8.14 G0.0001
Negative 97 26 REF
PET Pelvic LN involvement Positive 45 28 5.21 2.64Y10.30 G0.0001
Negative 69 12 REF
Para-aortic LN/distant metastasis Positive 16 13 5.12 2.59Y10.11 G0.0001
Negative 98 27 REF
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stage alone. Although the difference in concordance indices
between the FIGO stage and full model incorporating imaging
parameters (0.75 vs0.81) did not reach significance (P=0.058),
this level of improvement inC indices is considered substantial
and lends credence to the possibility that the small number of
events may explain the lack of significance. Previous studies
have indicated that FIGO staging may be influenced by MRI
findings especially in patients who undergo radiotherapy, and
parametrial invasion cannot be assessed at pathology; thus, it
may be difficult to retrospectively assess the independent pre-
dictive ability of these variables.1
Maximum tumor diameter was an independent prog-
nostic factor for PFS in our study. Tumor diameter is an
established prognostic parameter15,16 in cervical cancer and
correlates well with other pathological prognostic factors,
especially with parametrial involvement.17 Parametrial in-
volvement significantly influences outcome of patients with
cervical cancer,18 and the assessment of parametrial in-
volvement is crucial for the primary treatment. Therefore, it
was included in our prognostic 4-factor model. Parametrial
spread may be detected at histopathology even in women with
early FIGO stage,19 and it has been reported to be related with
other adverse prognostic factors, such as higher histological
grade, tumor size, and metastasis to pelvic LN.17 In early
invasive cervical cancers extended to parametria and para-
aortic LN at surgical staging, patients’ survival was reported
to be irrespective of other clinical-pathological factors, such
as histological subtypes.18 Our study supports the previous
results.8,18 Importantly, we showed that parametrial invasion
assessed noninvasively on MRI was the most robust prog-
nostic factor for PFS, exceeding the prognostic ability of other
clinical-histopathologic factors.
In our study, the presence of pelvic LN metastasis
on imaging was a predictor PFS in the univariate analysis,
and para-aortic lymphadenopathy/distant metastases was a
significant predictor of PFS on both univariate and multivari-
ate analyses. Many authors have reported that the presence of
pelvic/para-aortic LN metastases has an effect on patient’s
survival. Nonetheless, the prognostic importance of LN status
assessed on imaging is still controversial in cervical cancer.5,9
Some studies show that pelvic/para-aortic LN metastasis
assessed on FDG PET/CT is an independent predictive factor
for PFS in LACC.5,13 Kang et al5 introduced a model to predict
distant recurrence in patients with LACC, including histology,
tumor size, and pelvic/para-aortic LNmetastasis on FDG PET/
CT. The concordance index (0.73) was superior to that of FIGO
stage alone (0.57). Shim et al9 showed that para-aortic LN
metastasis on MRI, but not 18F-FDG PET/CT, was an inde-
pendent predictor of OS in patients with cervical cancer. The
concordance index of this model (0.69) was superior to that of
FIGO stage alone (0.59). It is important to note that the C in-
dices in our study were much higher than those previously
published.
Combined MRI and FDG PET/CT have been shown to
improve triage to the most appropriate primary therapy in
patients with early-stage cervical cancer.20 The prediction of
progression or recurrence in individual patients before any
therapy has started would add clinical value as a ‘‘risk as-
sessment model’’ including MRI and FDG PET/CT findings
can provide prognostic information that complements clinical
and histopathologic factors. This information is important
as currently combined PET/MRI equipment is becoming an
available tool for staging patients with gynecologic malig-
nancies. In this setting, PET/MRI protocols will need to be
balanced between high-resolution imaging of the pelvis that
provides crucial information on local disease extent (espe-
cially presence of parametrial invasion) and whole-body PET/
CT that provides valuable information on nodal and dis-
tant metastasis. Encouraging preliminary results have been
reported in multiple malignancies using whole-body MRI
techniques; however, further work is needed to evaluate its
added value in gynecologic malignancies.
Our study has several limitations. First, it is a retro-
spective study; hence, many factors could not be controlled
TABLE 3. Multivariate Cox modeling for PFS
Multivariate Models
Hazard Ratio 95% CI P C Index (95% CI)
Model Variable Level
FIGO FIGO stage IIB-IVB 12.07 4.70Y31.01 G0.0001 0.75 (0.69Y0.82)
I-IIA REF
Clinical Age at diagnosis 1.04 1.02Y1.07 0.0001 0.68 (0.59Y0.78)
Grade Grade 3 1.99 1.06Y3.73 0.0315
Grade 1/2 REF
Full Age at diagnosis 1.02 1.00Y1.05 0.08 0.81 (0.75Y0.87)
Grade Grade 3 1.98 1.04Y3.75 0.0375
Grade 1/2 REF
Parametrial invasion on MRI Positive 13.1 3.06Y56.16 0.0005
Negative REF
Para-aortic LN/distant metastasis on PET Positive 2.08 1.04Y4.18 0.0395
Negative REF
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for, including the influence of MRI findings on FIGO stage
especially in the subset of patients who underwent radio-
therapy, and thus, pathological FIGO stage could not be
obtained. Second, the retrospective nature allowed for a het-
erogeneous population, including patients who underwent
different treatment modalities. However, the aim of our study
was to evaluate potential prognostic value of multiple MRI
and FDG PET/CT findings, which are, by definition, inde-
pendent of treatment received. Third, a single reader evaluated
both MRI and FDG PET/CT scans. Although this makes
evaluation or interobserver variability impossible, it matches
routine clinical practice where a single experienced reader
specialized in gynecology-oncology imaging reports the ma-
jority (980%) of these studies and reviews them at the weekly
tumor board meeting. Finally, subsequent validation of our
results is warranted and should include a per-patient measure
such as a nomogram; at present, the best way to interpret
our results is that they support the notion that both MRI and
PET/CT provide complementary information.
CONCLUSIONS
In pretreatment assessment of patients with cervical
cancer, a prognostic model including combinedMRI and FDG
PET/CT findings in addition to clinical-pathological factors
adds significant incremental value to clinical-pathological
factors alone.
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